| Literature DB >> 34007189 |
Sirak Biset1, Ayantu Benti2, Lidya Molla2, Sitot Yimer2, Tena Cherkos2, Yalewayker Eyayu2, Ashenafi Ebabu3, Desie Kasew1, Aklilu Ambachew1.
Abstract
BACKGROUND: Meningitis, which is mostly caused by infectious agents, occurs more commonly during the first month of life. Bacterial meningitis is an important source of mortality and morbidity, especially in neonates of resource-limited countries. We aimed to determine the prevalence and etiological agents of bacterial meningitis and their antibiotic susceptibility pattern in neonates at the University of Gondar Comprehensive Specialized Hospital.Entities:
Keywords: Ethiopia; antibiotic susceptibility; bacterial meningitis; etiology
Year: 2021 PMID: 34007189 PMCID: PMC8121271 DOI: 10.2147/IDR.S307156
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Characteristics of Bacterial Meningitis Suspected Neonates Against the CSF Culture Result
| Variables | Frequency No (%) | CSF Culture Result | Chi-Square | ||
|---|---|---|---|---|---|
| Positive (n=19) | Negative (n=1082) | ||||
| Sex | Female | 506 (46%) | 12 (2.37%) | 494 (97.63%) | 0.099 |
| Male | 595 (54%) | 7 (1.18%) | 588 (98.82%) | ||
| Onset type | Early | 191 (17.3%) | 2 (1.05%) | 189 (98.95%) | 0.333 |
| Late | 910 (82.7%) | 17 (1.87%) | 893 (98.13%) | ||
| Admission site | NICU | 1025 (93.1) | 17 (1.66%) | 1008 (98.34%) | 0.524 |
| PEDI | 20 (1.8%) | 1 (5%) | 19 (95%) | ||
| WARD | 56 (5.1%) | 1 (1.79%) | 55 (98.21%) | ||
| Total | 1101 (100%) | 19 (1.73%) | 1082 (98.27%) | ||
Abbreviations: CSF, cerebrospinal fluid; NICU, neonatal ICU; WARD, neonatal ward; PEDI, pediatrics ward.
Distribution of Meningitis Causing Bacteria from Neonates Within the Sex, Onset Type, Admission Site, and Diagnosis Year
| Isolates No (%) 19 (100) | Sex (No) | Onset Type (No) | Admission Site (No) | Diagnosis Year (No) | MDR No (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female (506) | Male (595) | Early (191) | Late (910) | NICU (1025) | WARD (56) | PEDI (20) | 2013 (103) | 2014 (112) | 2015 (83) | 2016 (156) | 2017 (188) | 2018 (253) | 2019 (206) | |||
| GNB 14/19 (73.7%) | 4 | 3 | 1 | 6 | 6 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 4 | 5 (71.4) | |
| NLF-GNR 4 (21.05) | 3 | 1 | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 (100) | |
| 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | ||
| 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Other LF-GNB 1 (5.26) | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |
| GPB 5/19 (26.3%) | GBS 3 (15.8) | 1 | 2 | 1 | 2 | 3 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 (0.0) |
| 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | ||
| 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||
| Total isolate: No Prevalence (%) | 12 (2.37) | 7 (1.18) | 2 (1.05) | 17 (1.87) | 17 (1.66) | 1 (1.59) | 1 (5) | 1 (1) | 0 (0.0) | 0 (0.0) | 1 (0.64) | 5 (2.66) | 5 (1.98) | 7 (3.4) | 11 (57.9) | |
Abbreviations: GNB, Gram-negative bacteria; GPB, Gram-positive bacteria; GBS, Group B streptococcus; NLF, non-lactose fermenting; LF, lactose fermenting; NICU, neonatal ICU; WARD, neonatal ward; PEDI, pediatrics ward; MDR, multidrug resistant.
Figure 1Trend of NBM prevalence at the UoGCSH, from 2013 to 2019.
Antimicrobial Susceptibility Profile of Meningitis Causing Bacteria from Neonates at the UoGCSH
| Drug | Gram-Negative Bacteria | Gram-Positive Bacteria | Total (Drug Susceptibility Result) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NLF-GNR (n = 4) | Other LF-GNB (n = 1) | GBS (n = 3) | ||||||||||||||||
| S | R | S | R | S | R | S | R | S | R | S | R | S | R | S | R | S | R | |
| AMC | 0 | 1 | - | - | - | - | 0 | 1 | - | - | - | - | - | - | - | - | 0 | 2 (100%) |
| AMX | 0 | 2 | 0 | 2 | 0 | 1 | - | - | 0 | 1 | - | - | - | - | - | - | 0 | 6 (100%) |
| PIP | 0 | 1 | 0 | 2 | 0 | 1 | - | - | - | - | - | - | - | - | - | - | 0 | 4 (100%) |
| OXA | - | - | 1 | 0 | - | - | - | - | - | - | 1 | 0 | - | - | 1 | 0 | 3 (100%) | 0 |
| AMP | 0 | 3 | 1 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 1 (25%) | 3 (75%) |
| PEN | - | - | - | - | - | - | 0 | 1 | - | - | 0 | 1 | - | - | 1 | 0 | 1 (33.3%) | 2 (66.7%) |
| TOB | 0 | 3 | 0 | 3 | 0 | 1 | 1 | 0 | 1 | 0 | - | - | - | - | - | - | 2 (22.2%) | 7 (76.8%) |
| GEN | 1 | 2 | 0 | 2 | 1 | 0 | 1 | 0 | 1 | 0 | - | - | 1 | 0 | 0 | 1 | 5 (50%) | 5 (50%) |
| AMK | 1 | 0 | - | - | - | - | 1 | 0 | 1 | 0 | - | - | - | - | - | - | 3 (100%) | 0 |
| NOR | 1 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 0 |
| CIP | 1 | 2 | 0 | 1 | 0 | 1 | - | - | 0 | 1 | 1 | 0 | 1 | 0 | - | - | 3 (37.5%) | 5 (62.5%) |
| CAZ | 0 | 4 | 0 | 3 | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 7 (100%) |
| CFZ | - | - | 0 | 2 | 0 | 1 | - | - | - | - | - | - | - | - | - | - | 0 | 3 (100%) |
| CRO | 1 | 2 | 0 | 2 | 0 | 1 | - | - | 0 | 1 | 1 | 0 | - | - | - | - | 2 (25%) | 6 (75%) |
| CTX | 0 | 1 | 0 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 2 (100%) |
| IMP | 2 | 0 | 1 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 3 (100%) | 0 |
| MEM | 1 | 0 | 0 | 2 | - | - | - | - | - | - | - | - | - | - | - | - | 1 (33.3) | 2 (66.7%) |
| COT | 0 | 2 | 0 | 3 | 0 | 1 | - | - | 0 | 1 | - | - | 1 | 0 | - | - | 1 (11.1%) | 8 (88.9%) |
| DOX | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 0 | 1 | 0 |
| TET | - | - | - | - | - | - | - | - | - | - | 1 | 1 | - | - | - | - | 1 (50%) | 1 (50%) |
| VAN | - | - | - | - | - | - | - | - | - | - | 2 | 0 | 1 | 0 | - | - | 3 (100%) | 0 |
| CHL | 3 | 1 | 0 | 1 | - | - | - | - | - | - | 2 | 0 | - | - | - | - | 5 (71.4%) | 2 (28.6%) |
| CLI | - | - | - | - | - | - | - | - | 0 | 1 | 1 | 0 | - | - | - | - | 1 (50%) | 1 (50%) |
Abbreviations: AMC, augmentin; AMX, amoxicillin; PIP, piperacillin; OXA, oxacillin; AMP, ampicillin; PEN, penicillin; TOB, tobramycin; GEN, gentamycin; AMK, amikacin; NOR, norfloxacin; CIP, ciprofloxacin; CAZ, ceftazidime; CFZ, cefazolin; CRO, ceftriaxone; CTX, cefotaxime; IMP, imipenem; MEM, meropenem; COT, co-trimoxazole; DOX, doxycycline; TET, tetracycline; VAN, vancomycin; CHL, chloramphenicol; CLI, clindamycin; NLF-GNB, non-lactose fermenter Gram-negative bacteria; LF-GNB, lactose-fermenter Gram-negative bacteria; GBS, Group B streptococcus; S, sensitive; R, resistant.